Copper Mountain: Knight Vision—SIRT1 Aids ADAM10, Slays Aβ
Gizem Donmez reported that SIRT1 might protect against AD by boosting ADAM10 (aka α-secretase) and promoting non-amyloidogenic processing of Aβ APP...
1381 RESULTS
Sort By:
Gizem Donmez reported that SIRT1 might protect against AD by boosting ADAM10 (aka α-secretase) and promoting non-amyloidogenic processing of Aβ APP...
The Keystone Symposium at Copper Mountain, Colorado, was convened to discuss therapeutic approaches to Alzheimer disease besides those that target amyloid-β...
Pyroglutamate Aβ has been making a return to center stage in AD research after languishing in relative obscurity for a decade following its initial discovery...
Exactly which form the amino end of Aβ takes in the brains of people with AD is a question that increasingly crops up in talks about immunotherapy and even other dementias...
Could foresight be 2020 for Alzheimer disease? Zaven Khachaturian has proposed a national strategic plan of preventing the disease within 11 years...
Several posters beefed up the concept that signaling via calcineurin and NFATs may play a central role in neurodegenerative disease pathogenesis...
At the second annual Clinical Trials on Alzheimer’s Disease meeting, prevention—how, when, with what interventions—dominated the discussions...
Scientists at last month’s Society for Neuroscience conference in Chicago confirmed the vampire principle, whereby young blood keeps an aging organism vigorous...
Though the ApoE4 variant is the strongest genetic risk factor for late-onset Alzheimer disease, it offers no definitive test...
Designing compounds to fight neurodegenerative disease comes with the additional challenge of making sure they actually reach the brain...
In the past two years, a closer look at epilepsy and Alzheimer disease has revealed some fundamental similarities...
The SfN annual meeting featured a rare convergence of epilepsy and Alzheimer disease researchers at a symposium focused on shared features of these two disorders...
It’s refreshing to hear about studies showing clear convergence between biology, drug action, and behavior, all in the space of a few seconds, no less...
At a satellite symposium, “Nicotinic Acetylcholine Receptors (nAChRs) as Therapeutic Targets,” clinical discussion of cognitive treatments focused largely on nAChR agonists...
Days before the masses swarmed to the SfN annual meeting, a more intimate assembly of 287 exchanged the latest buzz on nicotinic acetylcholine receptors...